Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo".

Gray-Schopfer VC, Soo JK, Bennett DC.

J Invest Dermatol. 2008 Jun;128(6):1581; author reply 1583-4. doi: 10.1038/sj.jid.5701220. No abstract available.

2.

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.

Gray-Schopfer VC, Karasarides M, Hayward R, Marais R.

Cancer Res. 2007 Jan 1;67(1):122-9. Erratum in: Cancer Res. 2007 Feb 15;67(4):1877.

3.

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC.

Br J Cancer. 2006 Aug 21;95(4):496-505. Epub 2006 Aug 1.

4.

The role of B-RAF in melanoma.

Gray-Schopfer VC, da Rocha Dias S, Marais R.

Cancer Metastasis Rev. 2005 Jan;24(1):165-83. Review. Erratum in: Cancer Metastasis Rev. 2005 Jun;24(2):367.

PMID:
15785879
5.

p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.

Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D, Wynford-Thomas D, Bennett DC.

J Natl Cancer Inst. 2003 May 21;95(10):723-32.

PMID:
12759390

Supplemental Content

Loading ...
Support Center